TARS
NASD Tarsus Pharmaceuticals, Inc.$74.09 ↑ +1.09 (+1.49%) Trading Up from the previous close of $73.00, $0.38 below the day’s high of $74.47
- YTD change
- -9.51%
- vs 20-day SMA
- -5.93%
- vs 200-day SMA
- +8.09%
Price ranges
Price & Performance
+2.81 (+4.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 19.1% away from all-time highs of $91.53
- TARS is down 10% since the beginning of the year
- TARS is up 14% over the past 12 months
- TARS is down 11% over the past 1 month
- 15% of all TARS investors are betting against TARS
TARS reads not so good: price sits above one of the two key moving averages, the 12-month move is +7.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.52
- Last 5 days
- -2.11%
- vs 8-day SMA
- -2.27%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
